A b s t r a c t
The monoclonal antibody FMC7 identifies a 105-kd glycoprotein expressed in most normal mature B lymphocytes. 1, 2 Immunoblotting studies have demonstrated that FMC7 reacts with a carbohydrate determinant or a determinant of the protein that does not depend on its tertiary structure, since it withstands denaturation. 1 In a diagnostic setting, FMC7 is a reliable marker for distinguishing chronic lymphocytic leukemia (CLL) from other B-cell lymphoproliferative disorders, 3, 4 and, for that reason, it has been included in the immunological scoring system used to distinguish CLL from other B-cell conditions. 3, 5, 6 The monoclonal antibody CD20 recognizes a 35-to 37-kd nonglycosylated phosphoprotein that is expressed in mature B cells. 7 Its role in the differential diagnosis of B-cell disorders is lower than FMC7 because CD20 is positive in virtually all cases. 8 A recent report indicated that FMC7 binds to a particular conformation of the multimeric CD20 complex. This statement is based on the results of blocking studies that showed mutual inhibition of FMC7 and CD20 and on the expression of both FMC7 and CD20 in myeloid cells transfected with plasmids containing CD20-encoded complementary DNA. 9 Two studies have shown that FMC7 expression parallels that of CD20 in cells from patients with a variety of malignant and nonmalignant conditions. 10, 11 The authors suggested that the use of FMC7 for diagnosis may be unnecessary, provided that CD20 intensity also is considered. However, these conclusions were based on a small number of cases and the use of many samples from tissues or bone marrow specimens. 10 The aim of the present study was to analyze the expression of CD20 and FMC7 in cells from a large series of B-cell disorders to reexamine the possibility that the diagnostic value of CD20 is greater than or equal to that of FMC7. We also compared the standard scoring systems 3, 5, 6 with a modified scoring system in which FMC7 was replaced by CD20, providing evidence that the latter is less accurate for distinguishing between CLL and other B-cell disorders using flow cytometry.
Materials and Methods
Samples from 932 patients with B-cell disorders were analyzed retrospectively. These included 721 peripheral blood samples, 185 bone marrow specimens, 17 spleen or lymph node cell suspensions, and 9 samples from other fluids, comprising 630 cases of CLL, 23 cases of other B-cell leukemias, and 279 cases of B-cell non-Hodgkin lymphomas (B-cell NHL) with lymphocytosis ❚Table 1❚. All cases had a clonal B-cell population, with a median of 80% on gated cells (range, 11%-99%).
The diagnosis was based on clinical features, cell morphologic features according to the French-AmericanBritish proposals, 12 immunologic markers, 3 and histologic features according to the World Health Organization classification. 13 In certain diseases, additional tests were performed, ie, conventional cytogenetics, fluorescence in situ hybridization analysis for the t(11;14) and trisomy 12, 14 and cyclin D1 immunostaining, 15 to confirm the diagnosis, particularly in cases of B-cell NHL and atypical CLL.
Whole peripheral blood and bone marrow samples were incubated at room temperature for 10 minutes with the appropriate amount of each antibody, exposed to an ammonium chloride-based erythrocyte lysing solution, washed in phosphate-buffered saline, and resuspended in FACSFlow balanced electrolyte solution (Becton Dickinson, Mountain View, CA).
Single and/or double immunostainings with fluorescein isothiocyanate/phycoerythrin directly conjugated monoclonal antibodies were used. These monoclonal antibodies were CD5/CD19, CD23, CD22, CD20/CD79b, FMC7/CD2 and κ/λ light chains. When a diagnosis of hairy cell leukemia was suspected, CD11c, CD25, and CD103 also were used. 16 All monoclonal antibodies were supplied by Caltag (Burlingame, CA) except CD79b and CD103, which were provided by Immunotech (Marseille, France) and Immunoquality Products (Groningen, the Netherlands), respectively. Fluorescein isothiocyanate-and phycoerythrin-conjugated mouse immunoglobulins of the IgG1 subclass (Caltag) were used as negative controls in every experiment.
Immunophenotypic analysis was performed on a FACScalibur flow cytometer (Becton Dickinson) using a lymphocyte gate by forward and side scatter characteristics of the cells. Two-parameter dot plots and quadrant statistics were generated by CellQuest software (Becton Dickinson). Quadrants were set in such a way that cells labeled with the control antibodies were located in the left lower quadrant. A marker was considered positive when expressed in more than 30% of cells above the control result. When estimating the reactivity of CD5 on the surface of B cells, CD5/CD19 coexpression and the percentage of CD2+ T cells were taken into account.
The intensity of CD20, CD22, CD79b, and surface immunoglobulins (sIg) by κ and λ expression was estimated in a dot plot display selecting the logarithmic scale in the fluorescence axis and compared with the isotype control. The criteria adopted were as follows: weak, positive peak within the first logarithmic percentile; moderate, peak within the second percentile; and strong or very strong, peak within or more than 3 percentiles. 3 All cases were given a score according to their reactivity with CD5, CD23, and FMC7 and the intensity of sIg, CD79b, and/or CD22 expression. A value of 1 or 0 was given according to whether each marker was typical (CD5+, CD23+, FMC7-, weak expression of sIg, and weak or absent expression of membrane CD22 and/or CD79b) or atypical for CLL 3, 5, 6 ❚Table 2❚. A modified scoring system also was tested by replacing FMC7 with CD20 (1 point when negative, 0 points when positive).
All statistical analyses were performed using SPSS version 10.0 (SPSS, Chicago, IL). Contingency tables were analyzed by χ 2 or Fisher exact tests as appropriate. Logistic regression was used to assess statistically significant differences between both scoring systems. In all statistical calculations, a P value of less than .05 was considered significant.
Results

Correlation Between CD20 and FMC7 Reactivity
Considering all cases, CD20 was expressed in 94.5%, while FMC7 was expressed in 35.7% ❚Table 3❚. There were In contrast, cells from 85.7% of CLL cases were negative for FMC7, whereas most B-cell NHL and other B-cell leukemia cases were positive for FMC7 (79.2% and 96% [22/23] , respectively) ❚Image 1❚. These differences were statistically significant (P < .001; Fisher exact test).
CLL cases with typical morphologic features more frequently were negative for FMC7 than those with atypical morphologic features (88.2% vs 66% [46/69]). This difference was statistically significant (P < .001).
A correlation was found between CD20 and FMC7 expression in cases of B-cell NHL when a 30% cutoff level for positivity was used (P < .001; Table 3 ). However, in CLL cases, there was no correlation between CD20 and FMC7 positivity (P = .1; Table 3 ), even when atypical CLL was analyzed separately.
Analysis of CD20 as Part of the Scoring System
According to the scoring system from Matutes et al, 3 modified by Moreau et al 5 and updated by Matutes and Polliack, 6 91.7% of CLL cases scored 4 or 5, and only a minority (2.5%) had a low score (1-2). In contrast, most Bcell NHL and B-cell leukemia cases other than CLL had scores ranging from 0 to 2 ❚Table 4❚.
When CD20 was used instead of FMC7 in the scoring system, only 72.7% of CLL cases had scores of 4 or 5, 21.6% scored 3, and 5.7% had low scores (0-2) ❚Table 5❚. Thus, the proportion of CLL cases with a score of 3 rose significantly, from 5.7% to 21.6% when using CD20 for scoring (P = .001; Tables 4 and 5) .
By using the 5 standard markers, the accuracy of the scoring system for differentiating between CLL and non-CLL was 94.4% (95% confidence interval, 92.9%-95.9%) when a cutoff value of 4 points or higher was used. When replacing FMC7 with CD20, the accuracy was 81.5% (95% confidence interval, 79.0%-83.9%) (P < .001).
CD20 Intensity
Analysis of CD20 intensity in CD20+ cases showed that cells from 83.5% of the CLL cases had weak or moderate CD20 intensity compared with 13.6% of B-cell NHL cases and 17% of other B-cell leukemia cases (4/23) (P < .001) ❚Table 6❚.
Within the CD20+ CLL cases, CD20 intensity correlated with FMC7 expression; FMC7+ cases had a stronger CD20 intensity than FMC7-CLL cases (P < .001; χ 2 test) ❚Table 7❚. The intensity of CD20 also correlated with the scores. Cases with high scores had moderate or weak CD20 intensity, while those with low scores had strong CD20 intensities (P < .001; χ 2 test). 
Discussion
Immunophenotyping is essential for the diagnosis and subclassification of B-cell disorders. Although there is some overlap on membrane marker expression in the various Bcell disorders, some of them have a distinct immunophenotypic profile (eg, CLL, hairy cell leukemia). In this context, the CLL scoring system was devised to distinguish CLL from other B-cell disorders. 3, 5 Although early reports suggested that most CLL cases were CD79b-, 5,17 the use of a phycoerythrin-conjugated CD79b monoclonal antibody has shown that CD79b is expressed weakly in most CLL cases 6, 18 and, thus, should be considered as typical of CLL (1 point) when negative or weakly positive.
FMC7 was included in the score because of its discriminative power between CLL (negative) and other B-cell conditions. Indeed, FMC7 and sIg expression proved to be the most reliable markers for discriminating CLL from other B-cell neoplasms. 3 It has been reported that FMC7 binds to a multimeric CD20 complex. 9 Because of this, a few reports suggested that CD20 might well replace FMC7 for discriminating CLL from non-CLL diagnoses. 10, 11 In the present study, we analyzed the diagnostic value of the expression of CD20 as a discriminative marker (CLL vs non-CLL) and compared it with FMC7 in a large group of cases involving a variety of B-cell disorders. Our data show that in B-cell NHL, CD20 expression correlates well with that of FMC7, as with other B-cell markers (eg, CD22 and CD79b). In contrast, such a correlation was not found in CLL when considering the percentage of positive cells; only within the CD20+ CLL cases did the intensity of CD20 correlate with the expression of FMC7. Nevertheless, assessment of antigen density instead of proportion of positive cells may be more subjective and unreliable owing to reagent and operator variability. When FMC7 was replaced by CD20 in the scoring system, results were less discriminative as 27.3% of CLL cases had scores of 3 or lower. It seems that CD20 expression (assessed as negative or positive) does not improve the accuracy of the scoring system. Second, we assessed the intensity of CD20 expression in all CD20+ malignant neoplasms. As previously reported, CLL cells showed weaker CD20 expression compared with those in B-cell NHLs and other B-cell leukemias. 8, 19, 20 The weak expression of CD20 in CLL parallels, to some extent, that of CD22 or CD79b. Of interest is that cells from FMC7+ CLL had brighter CD20 expression and, subsequently, tended to have lower CLL scores than cases with lower CD20 intensities. Thus, when CD20 intensity is taken into account, there is a correlation between CD20 and FMC7 expression, even in CLL, which supports the results obtained by other authors. [9] [10] [11] Although FMC7 recognizes a particular glycosylated and multimeric CD20 complex, it is likely that this particular conformation is present only in cells with strong CD20 expression, which is not the case with CLL. Considering that the highly glycosylated protein CD22 also is weakly expressed in CLL, 8, 19 and that many other proteins, like Lselectin and leukocyte common antigen, are glycosylated aberrantly in CLL, 21, 22 it is possible that the abnormal glycosylation pattern of CD20 observed in CLL may account for the absence of FMC7 expression in this disease. Although FMC7 is a better discriminating marker for CLL and B-cell NHL by flow cytometry in cell suspensions, FMC7 cannot be used in tissue sections studied by immunohistochemical analysis. Therefore, analysis of CD20 is useful to determine the possible use of rituximab in patients with B-cell disorders and is recommended for use in immunohistochemical analysis and flow cytometry for clinical purposes. 
